AntiobesityResearch.com

CB1R                   CP-945598                 Pfizer [4]

CB1R                   Teranabant                 Merck [4]

CB1R                   Rimonnabant              Sanofi-Aventis [4]

CB1R                   Slv-319                        Solvay/BMS [4]

CB1R                   Surinabant                  Sanofi-Aventis [6]

CB1R                   AVE1625                     Sanofi-Aventis [4,6]

CB1R                   V24343                        Vernalis [7]

CB1R                   TM388837                     7TM [1]

CB1R                   Oleylethanolamide     N/K [5]

CB1R(FAAH)      N/K                               N/K [5]

      Abbreviations: K/N=not known; FAAH=fatty acid amide hydrolase.

1. 7TM press release. Pharma announces the selection of a new pre-clinical development candidate, TM38837, for treatment of obesity and Type 2 diabetes. Accessed: 2-06-08

2. Aronne LJ, Thornton-Jones ZD. New targets for obesity pharmacotherapy. Clin Pharmacol Ther. 2007 May;81(5):748-52.          

3. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007 Nov 17;370(9600):1706-13.

4. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther. 2008 Feb;117(2):207-31.

5. Nisoli E, Carruba MO. Emerging aspects of pharmacotherapy for obesity and metabolic syndrome. Pharmacol Res. 2004 Nov;50(5):453-69

6. Vemuri VK, Janero DR, Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav. 2008 Mar 18;93(4-5):671-86.

7. Vernalis Obesity and Diabetes: V24343 Accessed: 2-04-09

8. Engeli S, Bohnke J, Feldpausch M, et al.  Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54(10):2838-43.

9. Engeli S.Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol. 2008;20 S 1:110-5

10. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol. 2007 Mar 15;267(1-2):63-9.

11. Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, Seeley RJ, Obici S. Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism. Obesity (Silver Spring). 2009; 17: 1641-1645.